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Background: Sepsis is a syndrome that results in high morbidity and mortality. We investigated the delta neutrophil index (DN) as a 
predictive marker of early mortality in patients with gram-negative bacteremia.
Materials and Methods: We conducted a retrospective study at a tertiary referral hospital in South Korea from November 2010 to 
March 2011. The DN was measured at onset of bacteremia and 24 hours and 72 hours later. The DN was calculated using an auto-
matic hematology analyzer. Factors associated with 10-day mortality were assessed using logistic regression. 
Results: A total of 172 patients with gram-negative bacteremia were included in the analysis; of these, 17 patients died within 10 
days of bacteremia onset. In multivariate analysis, Sequental organ failure assessment scores (odds ratio [OR]: 2.24, 95% confidence 
interval [CI]: 1.31 to 3.84; P = 0.003), DN-day 1 ≥ 7.6% (OR: 305.18, 95% CI: 1.73 to 53983.52; P = 0.030) and DN-day 3 ≥ DN-
day 1 (OR: 77.77, 95% CI: 1.90 to 3188.05; P = 0.022) were independent factors associated with early mortality in gram-negative 
bacteremia. Of four multivariate models developed and tested using various factors, the model using both DN-day 1 ≥ 7.6% and 
DN-day 3 ≥ DN-day 1 was most predictive early mortality. 
Conclusions: DN may be a useful marker of early mortality in patients with gram-negative bacteremia. We found both DN-day 
1 and DN trend to be significantly associated with early mortality.
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Introduction
Sepsis is a common reason for hospitalization and admis-
sion to intensive care units (ICUs), and severe sepsis accounts 
for 20% of all ICU admissions [1]. Although efforts have at-
tempted to improve outcome, sepsis still results in high mor-
bidity and mortality.
Early recognition and risk stratification are necessary to im-
prove the outcomes in patients with sepsis [2, 3]. Several clini-
cal scores that reflect disease severity and predict sepsis out-
  http://dx.doi.org/10.3947/ic.2014.46.2.94  •  Infect Chemother 2014;46(2):94-102www.icjournal.org 95
come including physiology and chronic health evaluation 
(APACHE), the sequential organ failure assessment (SOFA), 
and simplified acute physiology scores (SAPS). However, 
none has sufficient accuracy to serve as a prognostic indica-
tor, and the current trend is to include the biological response 
in predictive scores, such as the PIRO (predisposition, insult, 
response, and organ dysfunction) concept [4]. 
More than 100 molecules have been investigated as biologi-
cal markers of sepsis [5]. The most widely used are C-reactive 
protein (CRP) and procalcitonin, although they have limited 
ability as diagnostic and prognostic markers [6]. Therefore, 
there are many ongoing studies to identify better biomarkers. 
Recent, studies have introduced the delta neutrophil index 
(DN), a measure that reflects the number of immature granu-
locytes (IG) in the peripheral blood [7]. Polymorphonuclear 
neutrophil granulocytes are the first-line effectors of host de-
fense against bacteria. After a maturation period of 7-10 days, 
they migrate into the peripheral blood [8]. The presence of IGs 
in the peripheral blood of adult patients represents increased 
myeloid cell production, generally accompanied by infection 
or severe inflammatory disease [9]. Increased IG levels are in-
cluded in the definition of systemic inflammatory response 
syndrome (SIRS) [10]. IG count can be measured with blood 
film morphology. However, this a manual method is impre-
cise due to the small number of cells counted, is labor inten-
sive, time-consuming, and non-reproducible; thus IG count 
has not been widely used [9]. An automatic analyzer measures 
differential leukocyte counts by two methods: a cytochemical 
myeloperoxidase (MPO) reaction and light beam reflection 
from nuclear lobularities in white blood cells (WBCs). DN is 
defined as the difference in counts between the two methods. 
DN strongly correlated with manual immature granulocyte 
count, and has shown an association with disseminated intra-
vascular coagulation scores, positive blood culture rates, and 
mortality in patients with suspected sepsis [7]. Additional 
studies have investigated DN as a diagnostic and prognostic 
marker for sepsis [8, 11, 12].
Some reports have studied the relationship between infec-
tion and DN [13-15]. DN may be able to differentiate true bac-
teremia from blood culture contamination [13]. DN at 72 h 
(cut-off value of 12%) could predict 7-day mortality in neona-
tal sepsis [14]. DN at the onset of spontaneous bacterial peri-
tonitis (cut-off value of 5.7%) was significantly associated with 
30-day mortality in liver cirrhosis [15].
In this study, we investigated DN as a predictive marker of 
early mortality in patients with gram-negative bacteremia 
(GNB). We evaluated DN trends and values for correlation 
with sepsis prognosis. In addition, we investigated the useful-
ness of DN in combination with other laboratory and clinical 
markers as a prognostic factor in sepsis. 
Materials and Methods
 
1. Study design
 We conducted a retrospective study to test the effectiveness 
of DN as a prognostic marker of early mortality in GNB. The 
study was approved by the Institutional Review Board of Sev-
erance Hospital (IRB 4-2012-0162). 
In-hospital mortality was assessed 10 days after onset of 
bacteremia. The patients were divided into two groups: death 
within 10 days (non-survivor; case) and survival on day 10 
(survivor; control). 
2. Patient eligibility criteria
All adult patients (≥ 18 years of age) admitted to Severance 
Hospital, a 2,000-bed tertiary referral university hospital in 
South Korea, from November 2010 to March 2011 were 
screened retrospectively. Patients with GNB were included in 
the study, and laboratory data and clinical data were collected 
from the database registry. Patients with subsequent episodes 
of bacteremia at any time during the same hospitalization pe-
riod were excluded. Blood cultures positive for previously iso-
lated organisms within 14 days of bacteremia onset were con-
sidered part of the first bacteremic episode. Patients who were 
bacteremic as outpatients or who were discharged from the 
hospital before obtaining culture results were excluded from 
the study. Patients with comorbidities that could affect the 
production of IG were also excluded. These conditions includ-
ed myelodysplastic syndromes, myeloproliferative diseases, 
myelofibrosis, metastatic bone marrow infiltration by a malig-
nancy, recovery after bone marrow hypoplasia or agranulocy-
tosis, severe systemic inflammation such as systemic lupus 
erythematosus or thrombotic thrombocytopenic purpura, 
acute rejection after organ transplantation, trauma, acute 
bleeding, and recent operations. 
3. Definitions
The day that the febrile event was first identified was defined 
as the onset of bacteremia and considered day 1. In cases with 
no febrile event, the day when blood cultures were taken was 
considered day 1. The third day from onset of bacteremia, that 
is, 2 days after the day of onset, was named day 3. Similarly, 
the seventh day was day 7.
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DN was calculated using an automatic hematology analyzer 
(ADVIA 2120; Siemens Healthcare Diagnostics, IL, USA) as 
previously described [7]: DN = leukocyte subfraction assayed 
in the MPO channel by cytochemical reaction - the leukocyte 
subfraction counted in the nuclear lobularity channel by re-
flected light beam [7].
4. Data collection
Data collected from individual patients included age, sex, 
body mass index (BMI), source of infection, duration of hospi-
tal stay before onset of bacteremia, history of ICU admission 
before onset of bacteremia, appropriateness of antibiotic 
treatment, presence of multidrug resistant (MDR) bacterial 
infection, and if the infection was healthcare-associated. We 
also investigated the Charlson comorbidity index to estimate 
baseline conditions [16]. Appropriate antibiotic therapy, MDR 
bacterial infection, and healthcare-associated infection were 
defined as in our previous study [12]. WBC count, percentage 
of neutrophils, DN, platelet count, erythrocyte sedimentation 
rate (ESR), and CRP were collected at day 1, day 3, and day 7. 
Clinical data including APACHE II scores [17] to measure se-
verity of the patients and SOFA scores [18] to measure the de-
gree of organ dysfunction were also collected on days 1, 3, and 7.
5. Four multivariate regression models
To evaluate the performance of DN as a predictor of mortal-
ity in GNB, we developed four multivariate models from fac-
tors associated with early mortality. APACHE II score was ex-
cluded in all models because it had significant correlation 
with SOFA score. We established an initial DN cut-off value 
with the greatest sensitivity and specificity in patients with 
GNB that was predictive of early mortality. We formed DN 
groups based on an initial DN greater or not greater than this 
cut-off value. We then divided all patients into 4 groups ac-
cording to initial DN and DN trend. 
6. Statistical analysis
Continuous variables were expressed as medians with inter-
quartile ranges (IQR) and the Mann-Whitney U test was used 
to compare continuous variables. Categorical variables were 
expressed as absolute numbers and percentages, and the chi-
square and Fisher’s exact tests were used to compare thesel 
variables. A linear mixed model was used to compare labora-
tory and clinical data trend over 7 days. To identify indepen-
dent risk factors for early mortality in patients with GNB, mul-
tivariate logistic regression models were used to control for 
effects of confounding factors. We made four multivariate 
Figure 1. Study population flow 
chart.
279 patients with gram negative bacteremia
172 patients were included
155 patients (90.1%) survived after 10 days
13 patients (7.6%) died within 10 to 30 days
17 patients (9.9%) died within 10 days
107 patients were excluded; 
recovery after agranulocytosis in 27 cases 
hematologic malignancy in 25 cases 
subsequent episode of bacteremia in 22 cases 
recent operation in 11 cases 
acute bleeding in 10 cases 
metastatic bone marrow infiltration in 10 cases 
being discharged before obtaining the culture results in 2 
cases
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models and the area under the curve (AUC) of the receiver 
operating characteristic (ROC) curve was calculated for each 
model to estimate the accuracy of the model for predicting 
early mortality in GNB. We divided the patients into 4 groups 
according to DN change over time. Cumulative overall surviv-
al rates were calculated using Kaplan-Meier estimates and a 
log-rank test was used to compare survival rates among the 4 
groups. All P-values were two-tailed and P < 0.05 was consid-
ered statistically significant. All statistical analysis were per-
formed using SPSS statistical software (version 18.0; SPSS Inc., 
Chicago, IL, USA).
Results
1. Patients
During the 5 months of the study period, 279 patients with 
GNB were screened for eligibility. Of these, 107 were excluded; 
hence, leaving 172 patients were included in the analysis. 
Among these patients, 17 died within 10 days (non-survivor), 
and 155 survived 10 days from bacteremia onset (survivor). 
Among the 155 survivors, 13 patients died between 10 to 30 
days of day 1 (Fig. 1). The median age of patients with GNB was 
64.65 years, and 77 patients (44.8%) were male. The mean score 
(± SD) of the Charlson comorbidity index was 3.58 (± 2.49).
2. Baseline characteristics and clinical data
The baseline characteristics of patients with GNB are de-
scribed in Table 1. The Charlson comorbidity index was higher 
in the non-survivor group than the survivor group (P = 0.010). 
Healthcare-associated and MDR bacterial infections were 
more frequent in non-survivors than in survivors (P = 0.002 
and P = 0.001, respectively). The duration of hospital stay be-
fore the onset of bacteremia was longer in non-survivors than 
in survivors (P < 0.001). Patients treated in the ICU before bac-
teremia onset accounted for 29.4% of the non-survivor group 
Table 1. Comparison of baseline characteristics between survivors and non-survivors in patients with gram negative bacteremia
Non-survivor 
(N=17)
Survivor 
(N=155)
P-value
Age (years)      (Median [IQR]) 67 (16)    67 (15) 0.843
Gender
Male 11 (64.7) 66 (42.6) 0.082
Female   6 (35.3) 89 (57.4)
BMI (kg/m2)   (Median [IQR])    23.2 (3)    20.5 (3.1) 0.594
Charlson comorbidity index    (Median [IQR])    6 (4)    3 (5) 0.010
Healthcare-associated infection 13 (76.5) 59 (38.1) 0.002
MDR bacterial infection   9 (52.9) 28 (18.1) 0.001
Appropriate antibiotic therapy 11 (64.7) 120 (77.4) 0.243
Admission duration before the onset of bacteremia (Median [IQR])    11 (12)    0 (2) <0.001
ICU stay before the onset of bacteremia   5 (29.4) 5 (3.2) <0.001
Source of bacteremia
Urinary tract infection   2 (11.8) 59 (38.1) 0.034
Biliary tract infection   2 (11.8) 45 (29.0) 0.160
Intra-abdominal infection 1 (5.9) 32 (20.6) 0.200
Pneumonia 11 (64.7) 10 (6.5) <0.001
Others 1 (5.9) 9 (5.8) 1.000
Causative microorganism
Escherichia coli   4 (23.5) 78 (50.3) 0.042
Klebsiella pneumoniae 1 (5.9) 35 (22.6) 0.128
Acinetobacter baumannii   7 (41.2) 3 (1.9)  <0.001
Others   5 (29.4) 39 (25.2) 0.771
Data are presented as N (%) of patients, unless otherwise indicated.
IQR, Interquartile range; BMI, Body mass index; MDR, Multidrug resistant; ICU, Intensive care unit.
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SOFA Figure 2. Comparison of 
laboratory and clinical data 
between survivor and non-
survivor groups in patients with 
gram negative bacteremia on 
day 1 day 3, day 7. 
WBC, white blood cell; ESR, 
erythrocyte sedimentation rate; 
CRP, C-reactive protein; APACHE, 
acute physiology and chronic 
health evaluation; SOFA, sequen-
tial organ failure assessment. 
aRegression slope and P -value 
were calculated by linear mixed 
model.
P = 0.564a P = 0.001a
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and 3.2% of the survivor group (P < 0.001). The most frequent 
source of bacteremia was urinary tract infection in survivors 
(38.1%) and pneumonia in non-survivors (64.7%) (P < 0.034). 
The predominant causative microorganism was Escherichia 
coli (n = 78, 50.3%) in survivors and Acinetobacter baumannii 
(n = 7, 41.2%) in non-survivors (Table 1).
 There were statistically significant differences in disease se-
verity between survivors and non-survivors. The propotion of 
patients with sepsis, severe sepsis and septic shock was 43.8% 
(n = 68), 35.4% (n = 55), 20.6% (n = 32) in survivors and 11.7% 
(n = 2), 11.7% (n = 2), 76.4% (n=13) in non-survivors (Fisher's 
exact test, P < 0.001). 
Laboratory and clinical data of patients with GNB on days 1, 
3, and 7 are shown in Figure 2. There was no statistically sig-
nificant difference in WBC count between non-survivors and 
survivors over the 7 days. The regression slope of the non-sur-
vivor group was positive (regression slope = 990) while that of 
the survivor group was negative (regression slope = -710, P = 
0.001). DN was higher in non-survivors on day 1 and day 3 
than in survivors (P = 0.012 and 0.003, respectively). The re-
gression slope of DN for non-survivors was -1.32 and -0.36, re-
spectively (P = 0.024). When non-survivors were divided into 
groups based on time to death (before 10 days and 10 - 30 
days), the DN was higher in those who died within 10 days on 
day 7 testing (mean DN (± SD) for deaths within 10 to 30 days: 
7 (± 6) on day 1, 3 (± 2) on day 3, 5 (± 7) on day 7; P-value = 
0.009, <0.001, and 0.001, respectively; data not shown). Plate-
let counts tended to decrease during the 7 days in non-survi-
vors (regression slope = -10.01), and counts were lower than 
in the survivor group on days 1, 3, and 7 (P = 0.003, < 0.001, 
and < 0.001, respectively). There was no difference in CRP lev-
els between the 2 groups during the 7 days. There was a ten-
dency towards increasing CRP levels in the non-survivor 
group and decreasing levels in the survivor group during the 7 
days (regression slope = 12.88 and -10.8; respectively, P = 
0.001). APACHE II scores were higher in non-survivors than in 
Table 2. Independent risk factors for mortality in gram negative bacteremia on multivariate analysis
Variables Adjusted odds ratio 95% CI P-value
Age (years) 1.096 0.979-1.226 0.111
Gender
Male 1.000
Female 0.915 0.061-13.802 0.949
BMI (kg/m2) 1.158 0.851-1.577 0.350
Charlson comorbidity index 1.618 0.813-3.218 0.170
Admission duration before the onset of bacteremia (days) 0.978 0.890-1.074 0.641
History of ICU stay before the onset of bacteremia
Yes 77.370 0.193-31089.796 0.155
No 1.000
Health care associated infections
Yes 4.179 0.275-63.585 0.303
No 1.000
MDR bacterial infection
Yes 0.535 0.031-9.280 0.668
No 1.000
SOFA score 2.244 1.312-3.837 0.003
Platelet count – day 3 (103/mm3) 0.998 0.981-1.016 0.858
DN group
DN–day 1 < 7.6% 1.000
DN–day 1 ≥ 7.6% 305.181 1.725-53983.520 0.030
Trend of DN
Day 1 > day 3 1.000
Day 3 ≥ day 1 77.774 1.897-3188.046 0.022
BMI, Body mass index; ICU, Intensive care unit; MDR, Multidrug resistant; SOFA, Sequential organ failure assessment; DN, Delta neutrophil index; CI, Confidence interval.
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survivors during the 7 days (P < 0.001). SOFA scores were 
higher in non-survivors than in survivors during the 7 days (P 
< 0.001, < 0.001, and 0.011, respectively). There was a tendency 
for SOFA scores to increase in non-survivors and to decrease 
in survivors (regression slope = 0.46 and -0.22, respectively; P 
= 0.001). There were no significant differences in value or re-
gression slope in the percentage of neutrophils and ESR be-
tween the 2 groups during the 7 days. 
3. Multivariate regression analysis
Factors associated with early mortality were assessed by 
multivariate logistic regression. Variables associated with ear-
ly mortality in univariate analysis (P < 0.05) and baseline de-
mographic data including age, sex, BMI, and Charlson comor-
bidity index, were included in the multivariate model. Among 
the laboratory data, platelet count and DN were included. 
The independent factors associated with early mortality 
were the SOFA score with an odds ratio (OR) of 2.24 (95% CI: 
1.31 to 3.84), DN-day 1 ≥ 7.6% with an OR of 305.18 (95% CI: 
1.73 to 53983.52) and DN-day 3 ≥ DN-day 1 with an OR of 
77.77 (95% CI: 1.90 to 3188.05) (Table 2).
We produced four multivariate models, shown in Supple-
mentary Table 1. Model 4 has the highest AUC of ROC curve 
among the four models; data are shown in Figure 3. The pa-
tients were divided into two groups based on a threshold DN 
value on day 1 of 7.6%. DN trend was also included, defined as 
whether or not DN had decreased on day 3. The AUC of this 
regression model was 0.987.
Based on the multivariate analysis, we divided the patients into 
4- groups by DN count on day 1 and the DN trend. Group 1 had a 
day 1 DN < 7.6% and a day 1 DN > DN on day 3. Group 2 had a 
day 1 DN < 7.6% and a day 1 DN ≤ DN on day 3. Group 3 had a 
DN on day 1 ≥ 7.6% and a DN on day 1 > DN on day 3. Group 4 
had a DN on day 1 ≥ 7.6% and a DN on day 1 ≤ DN on day 3. The 
differences in survival rates among the 4 groups are shown in 
Figure 3. Group 4 had the highest mortality rate (P < 0.001).
Discussion
Sepsis is a syndrome that can result in high morbidity and 
mortality, and risk prediction is necessary during monitoring 
and managing patients with sepsis [19]. Biomarkers such as 
CRP, procalcitonin, and various cytokines are elevated both in 
sepsis and noninfectious inflammatory diseases [2, 4-6] While 
these biomarkers could be useful as prognostic and  diagnos-
tic markers during sepsis treatment, they tend to be inconsis-
tent and heterogeneous [2-12, 16-20]. Prognostic markers 
have a significant role as indicators to inform effective treat-
ment and as an alarm system to predict death in patients with 
sepsis. For these reasons, there is a need to find suitable and 
specialized markers for sepsis.
DN is one laboratory marker of sepsis. In our previous study, 
we found that DN could be used as a predictor of mortality in 
patients with bacteremia 72 hours after onset of bacteremia 
[12]. In the present study, we sought to analyze the relation-
ship between DN and early mortality in GNB in more detail.
In our study, non-survivors had more comorbidities than 
survivors. Healthcare-associated infections, MDR bacterial in-
fections, source of bacteremia, and causative microorganisms 
were correlated with early mortality in patients with GNB. 
These findings were consistent with those of previous studies 
[21, 22]. Among laboratory variables, DN during 3 days, the 
absolute platelet count during 7 days, WBC count trends, DN, 
and CRP were significant factors associated with mortality. 
Absolute APACHE II and SOFA scores and trends were also 
associated with mortality. WBC count and CRP are widely 
used as prognostic indicators in the field, and we confirmed 
that trends are more important than absolute count for these 
variables. 
To evaluate the significance of DN as a predictor of mortality 
in GNB, we made multivariate models from factors associated 
with early mortality. APACHE II score was excluded from the 
models because it had significant correlation with SOFA score. 
The best cut-off value of initial DN for predicting early mortal-
ity in GNB was 7.6%, which corresponded to a sensitivity and 
Figure 3. Cumulative survival rate according to initial delta neutrophil 
(DN) and trend of DN in patients with gram negative bacteremia.
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specificity of 76.5% and 74.2%, respectively. We formed DN 
groups based on an initial DN greater or not greater than 7.6%. 
A DN on day 1 ≥ 7.6% was an independent predictor of early 
mortality. DN trend was also an independent factor for early 
mortality; therefore, we divided study patients into 4 groups 
according to both initial DN and the DN trend. We found that 
a DN on day 1 ≥ 7.6% and a DN on day 1≤ DN on day 3 to be 
more predictive of early mortality in patients with GNB.
Our study has several limitations. In our previous retrospec-
tive study, it was difficult to distinguish true infections from 
blood culture contamination in gram-positive bacteremia [12]. 
Because the present study was a retrospective study, we limit-
ed inclusion criteria to include only GNB cases. As a result, we 
cannot be sure that our findings are applicable to infectious 
diseases. The second limitation results from our exclusion of 
patients with serious underlying illnesses like hematologic 
malignancy and the mortality rate was relatively low in our 
study compared to other general reports [7, 11, 15]. Third, our 
study used 7.6% as the cut-off DN value to predict mortality in 
patients with GNB. Previous studies used a value of 2.7% to 
predict sepsis in patients with bacteremia [11] and 6.5% to 
predict severe sepsis in patients with sepsis [8]. To use DN as a 
universal marker, it is essential to determine an exact cut-off 
value that can be generally agreed upon. Finally, DN was cal-
culated using an ADVIA analyzer, which uses peroxidase and 
light scatter for WBC analysis, and its results may not be con-
sistent with immature granulocyte counts from other analyz-
ers using a different methods to determine leukocyte differen-
tial counts. Though calculation of DN is currently limited to 
the ADVIA analyzer, there are reports of other analyzers that 
could count immature granulocyte automatically [20, 23, 24]. 
 Despite these limitations, it is obvious that DN is as useful 
an indicator for predicting early mortality in patients with 
GNB as other existing methods. Furthermore, DN does not re-
quire additional time or cost as it can be calculated as soon as 
automatic leukocyte differential counts are completed. The 
time and cost-saving features of DN make it advantageous. 
Because sepsis is heterogeneous and fluctuating in nature, no 
single marker can be used as an independent prognostic indi-
cator. However, both DN trend and value on specific days 
could be a powerful prognostic factor.
In conclusion, we found DN to be a potentially useful mark-
er of early mortality in patients with GNB. Mortality rates were 
significantly higher when initial DN was greater than 7.6% and 
did not decreased until the third day after onset of bacteremia. 
Supplementary material
Supplementary data including one table can be found with 
this article online http://www.icjournal.org/src/sm/ic-46-
94-s001.pdf. 
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